Mike Bonney


Mike Bonney is Executive Chair of Kaleido’s Board of Directors and served as CEO from June 2017 until August 2018. Previously, Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the commercial infrastructure and launched the company’s first product Avonextm. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, ending his career there as National Business Director. Bonney also chairs the board of Alnylam Pharmaceuticals and is a member of the board of Bristol Myers Squibb. Bonney spends much of his time identifying and mentoring the next generation of leaders. He is also active in the governance and support of a variety of not-for-profit organizations, including Rare, Gulf of Maine Research Institute and Life Science Cares. Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). Bonney received a BA in Economics from Bates College where he was a Trustee for 17 years and chaired the Board for nine.